VRTX (Vertex Pharmaceuticals) Accumulated Depreciation: $0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRTX Vertex Pharmaceuticals Inc VRTX
90 GF Score
Price $548.05
GF Value $520.85
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Accumulated Depreciation?

Vertex Pharmaceuticals VRTX +1.44% 90 Accumulated Depreciation is $0 Mil as of Jun. 2026. GuruFocus rates VRTX with a GF Score™ of 90/100 and a GF Value™ of $520.85 (Fairly Valued). The stock has 5 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Vertex Pharmaceuticals's quarterly accumulated depreciation declined from Dec. 2025 ($-1,204 Mil) to Mar. 2026 ($0 Mil) but then stayed the same from Mar. 2026 ($0 Mil) to Jun. 2026 ($0 Mil).

Vertex Pharmaceuticals's annual accumulated depreciation declined from Dec. 2023 ($-1,189 Mil) to Dec. 2024 ($-1,065 Mil) but then increased from Dec. 2024 ($-1,065 Mil) to Dec. 2025 ($-1,204 Mil).

Vertex Pharmaceuticals Accumulated Depreciation Related Terms

Vertex Pharmaceuticals Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Accumulated Depreciation Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -896.00 -1,027.30 -1,188.90 -1,064.80 -1,204.10

Vertex Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1,204.10 0.00 0.00
VRTX
90GF Score
Vertex Pharmaceuticals Inc VRTX
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $0 Mil mean?
Vertex Pharmaceuticals (VRTX) has a Accumulated Depreciation of $0 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Accumulated Depreciation too high?
Vertex Pharmaceuticals' current Accumulated Depreciation is $0 Mil. Overall, Vertex Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Accumulated Depreciation compare to REGN and RVMD?
Vertex Pharmaceuticals' Accumulated Depreciation of $0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Accumulated Depreciation is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (VRTX) is currently considered Fairly Valued. The stock's GF Value™ is $520.85, compared to a current price of $548.05 — trading 5.2% above its estimated fair value. The current Accumulated Depreciation is $0 Mil. Vertex Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Vertex Pharmaceuticals (VRTX), the current Accumulated Depreciation is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be overvalued. The current stock price of $548.05 is trading 5.2% above its estimated GF Value™ of $520.85. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for VRTX:

  • Accumulated Depreciation: $0 Mil
  • GF Value™: $520.85 vs. price of $548.05 (5.2% above fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
90GF Score

Get the complete analysis for VRTX

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$548.05
Price
$520.85
GF Value